NVS Jan 2025 77.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

1.2000

0.0000

(0.00%)

As of 10:33AM EDT. Market open.

Zacks
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
Zacks
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.
Investing.com
Novartis shares slide on BofA downgrade
Shares of Novartis (SIX:NOVN) were down on Wednesday following a downgrade by BofA Securities, which downgraded the Swiss pharmaceutical giant to "neutral" from "buy." At 4:01 am (0801 GMT), Novartis was trading 2.4% lower at CHF 96.48. BofA also lowered its price target for Novartis to CHF110 from CHF120, reflecting growing apprehensions about the company's near-term potential for outperformance.